


Express Mail Label No.: EV399525778US
Date of Deposit: April 6, 2004

Page 1 of 3



Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0631-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/616,649
Filing Date	07/09/03
First Named Inventor	Chiao
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	24852-501 CIP2

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
MG	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/14/99	Breslow et al.	514	266	05/18/99
MG	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
X	B1*	WO 98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X
	B2*	WO 00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X
	B3*	WO 00/71703	Methylgene, Inc.	November 30, 2000	X
	B4*	WO 01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X
	B5*	WO 01/38322	Methylgene, Inc.	May 31, 2001	X
	B6*	WO 01/70675	Methylgene, Inc.	September 27, 2001	X
	B7*	WO 02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X
	B8*	WO 02/30879	Prolifix Limited	April 18, 2002	X
	B9*	WO 02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
X	C1*	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
	C2*	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract 4611.
	C4*	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
	C5*	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
	C6*	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
	C7*	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.


+ Did not receive

10616649

Express Mail Label No.: EV627295676US
Date of Deposit: June 9, 2005

Attorney Docket No.: 24852-501 CIP2
PAGE 1 of 2

Please type a plus sign (+) in this box ☐



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/616,649
	Filing Date	07/09/03
	First Named Inventor	Chiao
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP2

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
MG	A13	6,231,880	05/15/2001	Perrine	424	423	05/29/1998
MG	A14	2004/0002506	12/30/2004	Breslow et al. 1/2004	514	310	04/01/2004
MG	A15	2004/0087631	05/06/2004	Bacopoulos et al.	514	352	08/28/2003
MG	A16	2004/0122101	06/24/2004	Miller et al.	514	575	06/19/2003
MG	A17	2004/0132825	07/08/2004	Bacopoulos et al.	514	575	10/24/2003
MG	A18	2004/0266818	04/04/2004	Breslow et al. 12/2004	514	263.4	10/25/2002
MG	A19	2004/0072735	04/15/2004	Richon et al.	514	9	03/04/2003

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
MG	B10	WO 01/16106	Schering Aktiengesellschaft	03/08/2001		X

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MG	C60	Adams and Elliott (2000). <i>Oncogene</i> 19: 6687-6692.
	C61	Bates et al. (1999). <i>Proc. American Society of Clinical Oncology</i> 18: 180a, Abstract No. 693
	C62	Foster et al. (1997). <i>Invest. New Drugs</i> 15: 187-194.
	C63	Gojo et al. (2002). <i>Blood</i> 100: Abstract No. 2198.
	C64	Gore and Carducci (2000). <i>Exp. Opin. Invest. Drugs</i> 9: 2923-2934.
	C65	Huang and Pardee (2000). <i>Molecular Medicine</i> 6: 849-866.
	C66	Johnstone, R. (2002). <i>Nature Reviews Drug Discovery</i> 1: 287-299.
	C67	Kelly et al. (2002). <i>Exp. Opin. Invest. Drugs</i> 11: 1695-1713.
	C68	Kelly et al. (2002). <i>Proc. American Society of Clinical Oncology</i> 21: 6b, Abstract No. 1831.
	C69	Kelly et al. (2001). <i>Proc. American Society of Clinical Oncology</i> 20: 87a, Abstract No. 344.
	C70	Kosugi et al. (2001). <i>Jpn. J. Cancer Res.</i> 92: 529-536.
	C71	Marshall et al. (2002). <i>J. Exp. Therapeutics and Oncology</i> 2: 325-332.
	C72	Plekarz et al. (2001). <i>Blood</i> 98: 2865-2868.
	C73	Prakash et al. (2001). <i>Invest. New Drugs</i> 19: 1-11.
MG	C74	Rha et al. (1993). <i>J. Korean Med. Sci.</i> 8: 251-256.

5/16/06